Your browser doesn't support javascript.
loading
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
Procopio, Giuseppe; Chiuri, Vincenzo Emanuele; Giordano, Monica; Mantini, Giovanna; Maisano, Roberto; Bordonaro, Roberto; Calvani, Nicola; Facchini, Gaetano; De Placido, Sabino; Airoldi, Mario; Sbrana, Andrea; Gasparro, Donatello; Ludovico, Giuseppe Mario; Guglielmini, Pamela; Naglieri, Emanuele; Fagnani, Daniele; Aglietta, Massimo; Schips, Luigi; Beccaglia, Patrizia; Sciarra, Alessandro; Livi, Lorenzo; Santini, Daniele.
Afiliação
  • Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milan, 20133, Italy.
  • Chiuri VE; Medical Oncology Department, Ospedale Vito Fazzi, Lecce, Puglia, Italy.
  • Giordano M; Medical Oncology Division, ASST-Lariana, Como, Lombardia, Italy.
  • Mantini G; Radiochemotherapy Unit, Department of Diagnostics for Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico A. Gemelli IRCCS, Rome - University Department of Radiological and Hematological Sciences, Università Cattolica Sacro Cuore, Italy.
  • Maisano R; Department of Oncology, A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, Calabria, Italy.
  • Bordonaro R; MD - ARNAS Garibaldi, Catania, Sicilia, Italy.
  • Calvani N; Medical Oncology Unit, Antonio Perrino Hospital, Brindisi, Puglia, Italy.
  • Facchini G; Departmental Unit of Experimental Uro-Andrological Clinical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • De Placido S; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Campania, Italy.
  • Airoldi M; Oncology Unit 2 - Città della Salute e della Scienza di Torino, Turin, Piemonte, Italy.
  • Sbrana A; Medical Oncology Unit 2, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Gasparro D; Medical Oncology Unit, Department of General and Specialistic Medicine, University Hospital of Parma, Parma, Italy.
  • Ludovico GM; Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy.
  • Guglielmini P; Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
  • Naglieri E; Medical Oncology Unit, IRCCS Giovanni Paolo II, Bari, Italy.
  • Fagnani D; Medical Oncology Division, ASST Vimercate, Vimercate, Italy.
  • Aglietta M; Department of Oncology, University of Turin; Candiolo Cancer Institute - FPO- IRCCS, Candiolo, Italy.
  • Schips L; Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Urology unit, "SS. Annunziata Hospital", Chieti, Italy.
  • Beccaglia P; Janssen SpA, Cologno Monzese, Italy.
  • Sciarra A; Department of Urology, Sapienza Rome University Policlinico Umberto I, Rome, Italy.
  • Livi L; Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
  • Santini D; Department of Medical Oncology, University Campus Biomedico, Rome, Italy.
Ther Adv Med Oncol ; 12: 1758835920968725, 2020.
Article em En | MEDLINE | ID: mdl-33193831
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article